Page 39 - TD-2-2

Tumor Discovery A comprehensive review of bexarotene

cells: Relevance to mechanism of therapeutic action. Clin patients with cutaneous t-cell lymphoma. Arch Dermatol,
Cancer Res, 8(5): 1234–1240. 138(3): 325–333.
3. Lowe MN, Plosker GL, 2000, Bexarotene. Am J Clin https://doi.org/10.1001/archderm.138.3.325
Dermatol, 1(4): 245–250.
16. Shen D, Yu X, Wu Y, et al., 2018, Emerging roles of Bexarotene
https://doi.org/10.2165/00128071-200001040-00006 in the prevention, treatment and anti-drug resistance of
4. Fenaux P, Chomienne C, Degos L, 2001, All-trans cancers. Expert Rev Anticancer Ther, 18(5): 487–499.
retinoic acid and chemotherapy in the treatment of acute https://doi.org/10.1080/14737140.2018.1449648
promyelocytic leukemia. Semin Hematol, 38(1): 13–25.
17. Dummer R, Beyer M, Hymes K, et al., 2012, Vorinostat
https://doi.org/10.1016/s0037-1963(01)90002-2 combined with Bexarotene for treatment of cutaneous
5. Quéreux G, Saint-Jean M, Peuvrel L, et al., 2013, Bexarotene T-cell lymphoma: In vitro and phase I clinical evidence
in cutaneous T-cell lymphoma: Third retrospective study of supporting augmentation of retinoic acid receptor/retinoid
long-term cohort and review of the literature. Expert Opin X receptor activation by histone deacetylase inhibition. Leuk
Pharmacother, 14(13): 1711–1721. Lymphoma, 53(8): 1501–1508.
https://doi.org/10.1517/14656566.2013.810718 https://doi.org/10.3109/10428194.2012.656625
6. Chen L, Wang Y, Zhang J, et al., 2014, Bexarotenenanocrystal- 18. Butler RM, McKenzie RC, Jones CL, et al., 2019,
Oral and parenteral formulation development, Contribution of stat3 and rad23b in primary sézary cells
characterization and pharmacokinetic evaluation. Eur J to histone deacetylase inhibitor FK228 resistance. J Invest
Pharm Biopharm, 87(1): 160–169. Dermatol, 139(9): 1975–1984.e2.
https://doi.org/10.1016/j.ejpb.2013.12.005 https://doi.org/10.1016/j.jid.2019.03.1130
7. National Center for Biotechnology Information, 2023. 19. Budgin JB, Richardson SK, Newton SB, et al., 2015, Biological
Available from: https://pubchem.ncbi.nlm.nih.gov/ effects of Bexarotene in cutaneous T-cell lymphoma. Arch
compound/Bexarotene [Last accessed on 2023 Aug 01]. Dermatol, 141(3): 315–321.
8. Drug Future, 2023. Available from: https://www.drugfuture. https://doi.org/10.1001/archderm.141.3.315
com/chemdata/Bexarotene.html [Last accessed on 2023 Jun 30]. 20. McGinnis KS, Junkins-Hopkins JM, Crawford G, et al.,
9. Miller VA, Benedetti FM, Rigas JR, et al., 1997, Initial clinical 2004, Low-dose oral Bexarotene in combination with low-
trial of a selective retinoid X receptor ligand, LGD1069. dose interferon alfa in the treatment of cutaneous T-cell
J Clin Oncol, 15(2): 790–795. lymphoma: Clinical synergism and possible immunologic
mechanisms. J Am Acad Dermatol, 50(3): 375–409.
https://doi.org/10.1200/JCO.1997.15.2.790
https://doi.org/10.1016/j.jaad.2003.10.669
10. Wayne RB, 1994, The retinoids: Biology, chemistry and
medicine. J Am Coll Nutr, 13(6): 675–676. 21. Singh F, Lebwohl MG, 2004, Cutaneous T-cell lymphoma
treatment using Bexarotene and PUVA: A case series. J Am
11. Chambon P, 1996, A decade of molecular biology of retinoic Acad Dermatol, 51(4): 570–573.
acid receptors. FASEB J, 10: 940–954.
https://doi.org/10.1016/j.jaad.2003.05.010
12. Jacobo-Albavera L, Domínguez-Pérez M, Medina-Leyte DJ,
et al., 2021, The role of the ATP-binding cassette A1 (ABCA1) 22. Morita A, Tateishi C, Muramatsu S, et al., 2020, Efficacy and
in human disease. Int J Mol Sci, 22(4): 1593. safety of Bexarotene combined with photo (chemo) therapy
for cutaneous T-cell lymphoma. J Dermatol, 47(5):443–451.
https://doi.org/10.3390/ijms22041593
https://doi.org/10.1111/1346-8138.15310
13. Inoue M, Tanabe H, Nakashima K, et al., 2014, Rexinoids
isolated from Sophora tonkinensis with a gene expression 23. Straus DJ, Duvic M, Kuzel T, et al., 2007, Results of a phase
profile distinct from the synthetic rexinoid Bexarotene. II trial of oral Bexarotene (Targretin) combined with
J Nat Prod, 77(7): 1670–1677. interferon alfa-2b (Intron-A) for patients with cutaneous
T-cell lymphoma. Cancer, 109(9): 1799–1803.
https://doi.org/10.1021/np5002016
https://doi.org/10.1002/cncr.22596
14. Bowen CM, Walter L, Borras E, et al., 2021 Combination
of sulindac and Bexarotene for prevention of intestinal 24. Wang Y, Rong J, Zhang J, et al., 2007, Morphology,
carcinogenesis in familial adenomatous polyposis. Cancer in vivo distribution and antitumor activity of Bexarotene
Prev Res (Phila), 14(9): 851–862. nanocrystals in lung cancer. Drug Dev Ind Pharm, 43(1):
132–141.
https://doi.org/10.1158/1940-6207.CAPR-20-0496
https://doi.org/10.1080/03639045.2016.1225752
15. Breneman D, Duvic M, Kuzel T, et al., 2002, Phase 1 and
2 trial of Bexarotene gel for skin-directed treatments of 25. Hermann TW, Yen WC, Tooker P, et al., 2005, The retinoid

Volume 2 Issue 2 (2023) 13 https://doi.org/10.36922/td.0436